Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,674.45
(
-0.62%
)
US TECH 100
23,981.60
(
-0.62%
)
Dow Jones
46,586.28
(
-0.87%
)
Brent Oil
105.34
(
4.65%
)
Bitcoin
71,324.29
(
-3.54%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 164591

Tuesday, 09/10/2013 1:25:57 PM

Tuesday, September 10, 2013 1:25:57 PM

Post# of 257253
ABBV/ENTA plan to run a Japanese phase-3 trial of ABT-450/r + ABT-267 without ribavirin in GT1b treatment-naïve patients. (Source: ABBV webcast at Morgan Stanley that just finished.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now